Gilead Doubles Down On Its NASH Pipeline With $1.5B Deal

Gilead Sciences establishes strategic collaboration with Scholar Rock Holding Corporation in a deal totaling $1.5 billion.

To get the program started, Gilead only needs to give $80 million upfront to Rock Holding Corp., and then if preclinical moves along, another $25 million as a one-time payment.

Gilead’s closest NASH trial readouts are from two late-stage studies using selonsertib, which are expected to be released 1st half of 2019.

There are many other pharmaceutical companies that are set to release their own NASH fibrosis results in the 1st half of 2019 as well, which could compete against selonsertib.

Gilead is de-risked compared to other NASH biotechs in that it has multiple clinical products for NASH, while the others are limited to one drug.

https://seekingalpha.com/article/4230266-gilead-doubles-nash-pipeline-1_5b-deal